****

**NanoSphere Health Sciences Has Received Notice of Allowance for a Patent for its Breakthrough Nanoparticle Encapsulations of NSAIDs**

***Allowance for the patent marks significant advancement for the
treatment of pain and inflammation***

**Denver (April 24, 2019)** – Biotechnology leader [NanoSphere Health Sciences](http://www.nanospherehealth.com/), LLC (CSE: NSHS) (OTC: NSHSF) has received formal Notice of Allowance from the Canadian Intellectual Property Office (CIPO) for Application 2,970,91, covering “The Method of Treating Inflammatory Disorders and Global Inflammation with Phospholipid Nanoparticle Encapsulations of NSAIDs.” NSAIDs being non-steroidal anti-inflammatory drugs, which include ibuprofen, aspirin, and naproxen among others.

This patent allowance adds to NanoSphere’s already robust IP portfolio. In 2018 NanoSphere received a master patent covering NanoSphere’s core technology, the NanoSphere Delivery System™. This groundbreaking delivery platform encapsulates a broad range of bioactive compounds in a protective membrane, transporting them rapidly and effectively into the bloodstream and cells for the most rapid and effective results.

“Nano-encapsulating NSAIDs in a stable nanoparticle structure allows for a more rapid onset of symptom relief, longer lasting activity, greater therapeutic activity from a smaller dose and potential reduction of dangerous side effects,’ said Chief Science Officer Richard Clark Kaufman. “The current class of NSAID drugs are very effective, but they can also create an increased risk of gastrointestinal bleeding or ulcers, heart attacks, kidney disease, and liver failure,” said Kaufman. “Our research has been aimed at delivering these medicines both systemically and locally to target sites without passing through the gastrointestinal tract. By doing so we can create more effective treatments, with fewer adverse effects and enable long-term, safer use of NSAIDs.”

 “The granting of the patent further establishes NanoSphere as an advanced biotech company and secures our position as the leader in advanced nanoparticle delivery,” said Robert Sutton, CEO of NanoSphere Health Sciences. “Through our research and development, we aim to be the de facto mode for NSAID delivery worldwide, which according to Allied Market Research, the market is in excess of $100 billion, with an annual growth rate of 5.9%.”

With the issuance of this patent, NanoSphere will now have long-term market exclusivity over this delivery platform for NSAIDs with patent infringement prohibited. The company will now officially launch commercial development of a platform of pharmaceutical applications for the treatment of pain and inflammation. This patent allows for nanoparticle encapsulation of NSAIDs for transdermal, intranasal and intraoral applications, providing superior advantages over traditional pain management therapies.

“This patent confirms NanoSphere’s commitment to creating a portfolio of non-opioid analgesics that can be delivered by a variety of methods. Administration of NSAIDs through oral or intravenous routes is not always convenient or even possible. Utilizing its patented delivery system, NanoSphere will make available a safe and precise alternative for NSAID delivery,” said Senior Director of NanoSphere’s NSAID program, David Theil, M.D.

**On behalf of the Board**Robert Sutton, Chairman and CEO
**Direct:** 720.845-1466
**E-mail:** rsutton@nanospherehealth.com

**Investor Contact:**
Victor Goncalves, Executive Vice President
**Mobile:** 204-997-5517
**E-mail:** vgoncalves@nanospherehealth.com

**About NanoSphere** **Health Science, Inc.**
NanoSphere Health Sciences Inc., is a biotechnology firm specializing in the creation of the NanoSphere Delivery System™, a revolutionary platform using nanotechnology for the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. For more information on NanoSphere, please visit http://www.nanospherehealth.com.

**About Evolve Formulas**
Evolve Formulas, product line developed by NanoSphere Health Sciences, is the provider of the world's first and only scientifically proven nanoparticle delivery system in cannabis. Evolve’s pioneering product, Transdermal NanoSerum™, is a fast-acting, ultra-strength transdermal formula infused with nano-encapsulated cannabis and cannabis extracts. For more information on Evolve Formulas, visit https://www.evolveformulas.com/. Follow us on Facebook, Instagram and Twitter.

 *The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.*

**Forward Looking Statement Caution**

*This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company's intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without limitation those relating to the Company's future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements, whether as a result of new information, future events or otherwise.*